Digg icon reddit icon Stumbleupon icon
Print Email     Print Edition Stories

Monday, August 4, 2008

Russia says ‘da’ to Alkermes’ Vivitrol

By Mass High Tech Staff


Alkermes Inc.’s alcohol dependence drug Vivitrol has been approved by Russian regulatory authorities. Vivitrol is a once-monthly, extended-release injectable suspension formulation of naltrexone, developed using Alkermes’ Medisorb technology.

Alkermes (Nasdaq: ALKS) is partnering with Belgium-based Janssen-Cilag, a Johnson & Johnson company. The Cambridge-based biotech will manufacture Vivitrol for Janssen-Cilag, which will sell the drug in Russia. Besides revenues from manufacturing the drug, Alkermes will receive royalties based on its sales.

Financial details of the Janssen-Cilag deal were not released. In the U.S., Vivitrol is marketed primarily by Frazer, Pa.-based Cephalon Inc.

According to Janssen-Cilag, approximately 10 million people are dependent on alcohol in Russia. Because its abuse has been “causally related” to myriad diseases including cancer, heart disease and liver disease, it has been identified as contributing to 30 percent of all deaths in the country per year, the company stated.

In June, Alkermes reported its start of a Phase 3 clinical trial of its Vivitrol long-term treatment for opioid dependence. Alkermes employs 610 workers and reported 2008 net income of $167 million on revenue of $240.7 million.
 

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.

Digg icon reddit icon Stumbleupon icon
Contact Editor Latest News

Tech Pulse Poll

What's your level of interest in Pinterest?



View Results

Stay Informed
Check which newsletter you'd like to receive.
TechFlash (Daily)
BioFlash (Daily)
GreenFlash (Weekly)
Startup Report (Weekly)
Breaking news, MHT events, local announcements
RSS feeds
Your email:

Affiliate publications: ACBJ.com, Boston Business Journal, Bizjournals.com, Portfolio.com, Wired.com

Web Site Developed by Neptune Web, Inc.

Use of and/or registration on any portion of this site constitutes acceptance of our User Agreement and Privacy Policy. About our ads.